Signaling multiplex of the epidermal growth factor receptor

Expert Review of Anticancer Therapy

Volumn 4, Issue 6, 2004, Pages 1145-1156

  Higa, Gerald M ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Akr; Apoptosis; ATP binding pocket; Cetuximab; Crystal structure; EGFR; EGFR mutations; erbB family; Heterodimer; JAK STAT

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BEVACIZUMAB; CANERTINIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; FIBROBLAST GROWTH FACTOR; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMATINIB; IRINOTECAN; JANUS KINASE 2; LAPATINIB; OXALIPLATIN; PELITINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; ASTHENIA; CANCER CELL; CANCER RADIOTHERAPY; CELL GROWTH; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DEREGULATION; DRUG APPROVAL; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG TARGETING; ENZYME ACTIVITY; FATIGUE; GROWTH INHIBITION; HUMAN; INTERNALIZATION; LUNG CANCER; META ANALYSIS; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW;

EID: 10644253660     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.6.1145     Document Type: Review

References (99)

1. Aroian RV, Sternberg PW. Multiple functions of let-23, a Caenorhabditis elegans receptor tyrosine kinase gene required for vulval induction. Genetics 128, 251-267 (1991).
2. Schweitzer R, Howes R, Smith R, Shilo BZ, Freeman M. Inhibition of Drasophila EGF receptor activation by the secreted protein Argos. Nature 376, 699-702 (1995).
3. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19, 183-232 (1995).
4. Harris AL, Nicholson S, Sainsbury R, Wright C, Farndon J. Epidermal growth factor receptor and other oncogenes as prognostic markets. Natl Cancer Inst. Monogr. 11, 181-187 (1992).
5. Wong AJ, Bigner SH, Bigner DD, Kinzier KW, Hamilton SR, Vogelstein B. Increased expression of the EGF receptor gene in malignant gliomas is invariably associated with gene amplification. Proc. Natl Acad. Sci. 84, 6899-6903 (1987).
6. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor-α. J. Clin. Invest. 90, 1352-1360 (1993).
7. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 103, 211-225 (2000).
8. Riese DJ II, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20, 41-48 (1998).
9. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16, 1647-1655 (1997).
10. ERB3 possesses an impaired tyrosine kinase activity. Proc. Natl Acad. Sci. 91, 8132-8136 (1994).
11. Miettinen PJ, Berger JE, Meneses J et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376, 337-341 (1995).
12. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378, 394-398 (1995).
13. Jones FE, Stern DF. Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloaveolar development and lactation. Oncogene 18, 3481-3490 (1999).
14. Jones FE, Welte T, Fu XY, Stern DF. ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation. J. Cell Biol. 147, 77-87 (1999).
15. Luetteke NC, Qiu TH, Peiffer RL, Oliver P, Smithies O, Lee DC. TGFα deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice. Cell 73, 263-278 (1993).
16. Mann GB, Fowler KJ, Gabriel A, Nice EC, Williams RL, Dunn AR. Mice with a null mutation of the TGF-α gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation. Cell 73, 249-261 (1993).
17. Sibilia M, Steinbach JP, Stingl L, Aguzzi A, Wagner EF. A strain-dependent postnatal neurodegeneration in mice lacking EGF receptor. EMBO J. 17, 719-731 (1998).
18. Lax I, Burgess WH, Bellot F, Ullrich A, Schlessinger J, Givol D. Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling. Mol. Cell Biol. 8, 1831-1834 (1988).
19. Lax I, Bellot F, Howk R, Ullrich A, Givol D, Schlessinger J. Functional analysis of the ligand binding site of EGF-receptor utilizing chimeric chicken/human receptor molecules. EMBO J. 8, 421-427 (1989).
20. Ogiso H, Ishitani R, Nureki O et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110, 775-787 (2002).
21. Wiesmann C, Fuh G, Christinger HW, Eigenbrot C, Wells JA, de Vos AM. Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 91, 695-704 (1997).
22. Garrett TPJ, McKern NM, Lou M et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor-α. Cell 110, 763-773 (2002).
23. Olayioye MA, Graus-Porta D, Beerli RR, Rohrer J, Gay B, Hynes NE. ErbB-1 and erbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol. Cell. Biol. 18, 5042-5051 (1998).
24. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett. 410, 83-86 (1997).
25. Gamett DC, Pearson G, Cerione RA, Friedberg I. Secondary dimerization between members of the epidermal growth factor receptor family. J. Biol. Chem. 272, 12052-12056 (1997).
26. Hirsch FR, Varella-Garcia M, Franklin WA et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br. J. Cancer 86, 1449-1456 (2002 ).
27. Tzahar E, Waterman H, Chen X et al. A hierarchical network of inter-receptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell. Biol. 16, 5276-5287 (1996).
28. Hughes DPM, Thomas DG, Giordano TJ, Baker LH, McDonagh KT. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res. 64, 2047-2053 (2004).
29. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol. Rev. 81, 153-208 (2001).
30. Johnson L, Greenbaum D, Cichowski K et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev. 11, 2468-2481 (1997).
31. Koch AC, Anderson D, Moran MF, Ellis C, Pawson T. SH-2 and SH-3 domains: elements that control interactions of cytoplasmic signaling proteins. Science 252, 668-674 (1991).
32. Avruch J, Khokhlatchev A, Kyriakis JM et al. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAPK cascade. Recent Prog. Horm. Res. 56, 127-155 (2001).
33. Chang F, Lee JT, Navolanic PM et al. Involvement of P13K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17, 590-603 (2003).
34. Martinez-Lorenzo MJ, Anel A, Monleon I et al. Tyrosine phosphorylation of the p85 subunit of phosphatidylinositol 3-kinase correlates with high proliferation rates in sublines derived from the Jurkat leukemia. Int. J. Biochem. Cell. Biol. 32, 435-445 (2000).
35. Datta SR, Dudek H, Tio X et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231-241 (1997).
36. Franke TF, Kaplan DR, Cantley LC. P13K: downstream AKTion blocks apoptosis. Cell 88, 435-437 (1997).
37. Scott PH, Brunn GJ, Kohn AD et al. Evidence insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc. Natl. Acad. Sci. 95, 7772-7777 (1998).
38. Jiang B-H, Zheng JZ, Aoki M, Vogt PK. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc. Natl Acad. Sci. 97, 1749-1753 (2000).
39. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signaling. Exp. Cell Res. 284, 31-53 (2003).
40. Ahonen TJ, Xie J, LeBaron MJ et al. Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. J. Biol. Chem. 278, 27287-27292 (2003).
41. Burke P, Schooler K, Wiley HS. Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol. Biol. Cell 12, 1897-1910 (2001).
42. Robertson KW, Reeves JR, Smith G et al. Quantitative estimation of epidermal growth factor receptor and c-erb-2 in human breast cancer. Cancer Res. 56, 3823-3830 (1996).
43. Irish JC, Bernstein A. Oncogenes in head and neck cancer. Laryngoscope 103, 42-52 (1993).
44. Fontanini G, Vignati S, Bigini D et al. Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur. J. Cancer 31A, 178-183 (1995).
45. Wong AJ, Ruppert, Bigner SH et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl Acad. Sci. 89, 2965-2969 (1992).
46. Di Marco E, Pierce JH, Fleming TP et al. Autocrine interaction between TGF-α and the EGF-receptor. quantitative requirements for induction of the malignant phenotype. Oncogene 4, 831-838 (1992).
47. Hanahan D, Weinbert RA. The hallmarks of cancer. Cell 100, 57-70 (2000).
48. Todaro GJ, De Larco JE. Growth factors produced by sarcoma virus-transformed cells. Cancer Res. 38, 4147-4154 (1978).
49. Gimbrone MA, Leapman SB, Cotran RS, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med. 136, 261-276 (1972).
50. Garcia-Barros M, Paris F, Cordon-Cardo C et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300, 1155-1159 (2003).
51. Bruns CJ, Solorzano, CC, Harbison MT et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 60, 2926-2935 (2000).
52. Rak J, Mitsuhashi Y, Sheehan C et al. Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor upregulation in ras-transformed epithelial cells and fibroblasts. Cancer Res. 60, 490-498 (2000).
53. Viloria Petit AM, Rak J, Hung M-C et al. Neutralizing antibodies against epidermal growth factor and erbB-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo. Am. J. Pathol. 151, 1523-1530 (1997).
54. Wang D, Su Huang H-J, Kazlauskas A, Cavenee WK. Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res. 59, 1464-1472 (1999).
55. Pidgeon GP, Barr MP, Harmey JH, Foley DA, Bouchier-Hayes DJ. Vascular endothelial growth factor (VEGF) upregulates bcl-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br. J. Cancer 85, 273-278 (2001).
56. Katoh O, Takahashi T, Oguri T et al. Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an anti-apoptotic factor. Cancer Res. 58, 5565-5569 (1998).
57. Dias S, Choy M, Alitalo K, Rafii S. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 99, 2179-2184 (2002).
58. Ellis RE, Yuan JY, Horvitz HR. Mechanisms and functions of cell death. Ann. Rev. Cell Biol. 7, 663-698 (1991).
59. Mapara MY, Bargou R, Zugck C et al. APO-1 mediate apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression. Eur. J. Immunol. 23, 702-708 (1993).
60. Madrid LV, Wang CY, Guttridge DC, Schottelium AJ, Baldwin AS Jr, Mayo MW. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-κB. Mol. Cell. Biol. 20, 1626-1638 (2000).
61. Sorkin A, McKinsey T, Shih W, Kirchhausen T, Carpenter G. Stoichiometric interaction of the epidermal growth factor receptor with the clathrin-associated protein complex AP-2. J. Biol. Chem. 270, 619-625 (1995).
62. Sunada H, Magun BE, Mendelsohn J, MacLeod CL. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc. Natl Acad. Sci. 83, 3825-3829 (1986).
63. 1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 12, 1397-1403 (1996).
64. Shin DM, Donato NJ, Cooper M et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. 7, 1204-1213 (2001).
65. Cunningham D, Humbler Y, Siena S et al. Cetuximab (C225) alone or in combination with irinotecan (CPT- 11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan refractory metastatic colorectal cancer (MCRC). Proc. Am. Sec. Clin. Oncol. 22 (2003) (Abstract 1012).
66. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22, 1201-1208 (2004).
67. Rosenberg AH, Loehrer PJ, Needle MN, Waksal H, Hollywood E. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc. Am. Soc. Clin. Oncol. 21 (2002) (Abstract 536).
68. Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int. J. Radiat. Oncol. Biol. Phys. 49, 427-433 (2001).
69. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J. Clin. Oncol. 21, 2237-2246 (2003).
70. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290, 2149-2158 (2003).
71. Giaccone F, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a Phase III trial-INTACT 1. J. Clin. Oncol. 22,777-784 (2004).
72. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: a Phase III trial-INTACT 2. J. Clin. Oncol. 22, 785-794 (2004).
73. Shepherd FA, Pereira J, Ciuleanu TE et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proc. Am. Soc. Clin. Oncol. 22 (2004) (Abstract 7022).
74. Hurwitz H, Fehrenbacher T, Cartwright J et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
75. Overholser JP, Prewett MC, Hooper AT, Waksal HW, Hicklin DJ. Epidermal growth factor receptor blockage by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 89, 74-82 (2000).
76. Inoue K, Slaton JW, Perrotte P et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor antibody monoclonal antibody Imclone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res. 6, 4874-4884 (2000).
77. Humphrey PA, Wong AJ, Vogelstein B et al. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res. 48, 2231-2238 (1988).
78. Sugawa N, Ekstrand AJ, James CD, Collins VP. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc. Natl Acad. Sci. 87, 8602-8606 (1990).
79. Moscatello DK, Holgado-Madruga M, Godwin AK et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 55, 5536-5539 (1995).
80. Su Huang HJ, Nagane M, Klingbeil CK et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J. Biol. Chem. 272, 2927-2935 (1997).
81. Helin K, Beguinot L. Internalization and downregulation of the human epidermal growth factor receptor are regulated by the carboxyl-terminus tyrosines. J. Biol. Chem. 266, 8363-8368 (1991).
82. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson FJ, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 61, 8887-8895 (2001).
83. Wallasch C, WeiB, Niederfellner G, Jallal B, Issing W, Ullrich A. Heregulin-dependent regulation of heR2/neu oncogenic signaling by heterodimerization with heR3. EMBO J. 14, 4267-4275 (1995).
84. Alimandi M, Romano A, Curia MC et al. Co-operative signaling of erbB3 and erbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10, 1813-1821 1995).
85. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G. All erbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J. Biol. Chem. 271, 5251-5257 (1996).
86. Chen YF, Pan GZ, Hou X et al. Epidermal growth factor and its receptors in human pancreatic carcinoma. Pancreas 5, 278-283 (1990).
87. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 235, 177-182 (1987).
88. Lowy DR, Willumsen BM. Function and regulation of ras. Ann. Rev. Biochem. 62, 851-891 (1993).
89. Ferguson KM, Darling PJ, Mohan MJ, Macatee TL, Lemmon MA. Extracellular domains drive homo- but not hereto-dimerization of erbB receptors. EMBO J. 19, 4632-4643 (2000).
90. Gangarosa LM, Sizemore N, Graves-Deal R, Oldham SM, Der CJ, Coffey RJ. A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells. J. Biol. Chem. 272, 18926-18931 (1997).
91. Nishikawa R, Ji X-D, Harmon RC et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl Acad. Sci. 91, 7727-7731 (1994).
92. Prenzel N, Zwick E, Daub H et al. EGF receptor transactivation by G-protein coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402, 884-888 (1999).
93. Liu D, Aguirre Ghiso JA, Estrada Y, Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of human carcinoma. Cancer Cell 1, 445-457 (2002).
94. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
95. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163-1167 (2004).
96. Udari M, Utikal J, Krahn GM, Peter RU. Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. Neoplasia 3, 245-254 (2001).
97. Singh RK, Tsan R, Radinsky R. Influence of the host microenvironment on the clonal selection of human colon carcinoma cells during primary tumor growth and metastasis. Clin. Exp. Metastasis 15, 140-150 (1997).
98. Tipping AJ, Mahon FX, Lagarde V, Goldman JM, Melo JV. Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells. Blood 98, 3864-3867 (2001).
99. Branford S, Rudzki Z, Walsh S et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102, 276-283 (2003).